THE TRACEER AML DIARIES

Despite acquiring a complete reaction with optimal induction therapy, minimal residual sickness normally persists, necessitating consolidation therapy to mitigate the risk of relapse by eradicating residual ailment. In sufferers who may have obtained seven+3 induction therapy, consolidation therapy is initiated with higher-dose cytarabine, often c